Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil for FSD in Females With Genital Mutilation
NCT05266651Phase 3Unknown
- Sponsor
- Kasr Al Ainy Hospital
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in female sexual dysfunction (FSD) comparing Tadalafil Group with Placebo Group (2 arms). Primary endpoint: Clitoral Artery Doppler at 1 month. Status: unknown.
02
Drugs
tadalafil
03
Conditions
female sexual dysfunction (FSD)
Beyond the preview
Go deeper on NCT05266651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266651.